Upadacitinib
Phase 1Active 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Juvenile Idiopathic Arthritis (JIA)
Conditions
Juvenile Idiopathic Arthritis (JIA)
Trial Timeline
Jun 24, 2019 → May 1, 2027
NCT ID
NCT03725007About Upadacitinib
Upadacitinib is a phase 1 stage product being developed by AbbVie for Juvenile Idiopathic Arthritis (JIA). The current trial status is active. This product is registered under clinical trial identifier NCT03725007. Target conditions include Juvenile Idiopathic Arthritis (JIA).
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04159597 | Pre-clinical | Active |
| NCT06332534 | Phase 3 | Recruiting |
| NCT06773403 | Approved | Recruiting |
| NCT05782907 | Phase 3 | Active |
| NCT05507580 | Approved | Completed |
| NCT05094128 | Pre-clinical | Recruiting |
| NCT04195698 | Phase 3 | Completed |
| NCT03725007 | Phase 1 | Active |
Competing Products
20 competing products in Juvenile Idiopathic Arthritis (JIA)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| PLX-200 + Placebo | Polaryx Therapeutics | Phase 3 | 69 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 77 |
| MRA(Tocilizumab) + placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 77 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 77 |
| Adalimumab | Eisai | Phase 3 | 77 |
| Abatacept | Ono Pharmaceutical | Phase 3 | 77 |
| Ixekizumab + Adalimumab | Eli Lilly | Phase 3 | 77 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| Baricitinib | Eli Lilly | Phase 3 | 77 |
| Baricitinib + Tocilizumab | Eli Lilly | Phase 3 | 77 |
| adalimumab + Methotrexate | AbbVie | Pre-clinical | 23 |
| Upadacitinib + Tocilizumab | AbbVie | Phase 3 | 77 |
| Adalimumab + Risankizumab | AbbVie | Phase 3 | 77 |
| Adalimumab | AbbVie | Phase 3 | 77 |
| naproxen + esomeprazole | AstraZeneca | Phase 1 | 33 |
| Alendronate (Fosamax) | Merck | Pre-clinical | 23 |
| canakinumab | Novartis | Phase 3 | 77 |
| Secukinumab | Novartis | Phase 1 | 33 |
| ACZ885 150 mg (Canakinumab) | Novartis | Phase 3 | 77 |